Nick Vitanza, the Director of the Vitanza Lab at the Ben Towne Center for Childhood Cancer Research, posted on X/Twitter:
“It’s been a dream to bring better treatments to kids with DIPG and CNS tumors. It’s thrilling to announce BrainChild Bio a kids first biotech advancing CAR-T cells for CNS tumors (CEO Steve Brugger; CSO Mike Jensen, MD) in partnership with Seattle Children’s Hospital.”
Read more here.
Source: Nick Vitanza/X